Anti-factor D antibodies

Patent metadata

Field	Value
Publication number	US-10179821-B2
Application number	US-201514700853-A
Country	US
Kind code	B2
Filing date	Apr 30, 2015
Priority date	May 1, 2014
Publication date	Jan 15, 2019
Grant date	Jan 15, 2019

Abstract

The invention relates to anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.

First claim

We claim:

1. An anti-Factor D antibody comprising a light chain variable domain amino acid sequence of SEQ ID NO:19, and a heavy chain variable domain amino acid sequence of SEQ ID NO:20.

2. An anti-Factor D antibody comprising: a light chain variable domain comprising a HVR-L1 having the sequence of SEQ ID NO: 14, a HVR-L2 having the sequence of SEQ ID NO:6, and a HVR-L3 having the sequence of SEQ ID NO:7; and a heavy chain variable domain comprising a HVR-H1 having the sequence of SEQ ID NO:8, a HVR-H2 having the sequence of SEQ ID NO:12, and a HVR-H3 having the sequence of SEQ ID NO:15.

3. An anti-Factor D antibody having a light chain having the amino acid sequence of SEQ ID NO: 28 and a heavy chain having the amino acid sequence of SEQ ID NO: 29.

4. A pharmaceutical formulation comprising the antibody according to any one of claim 1 , 2 and 3 .

5. The pharmaceutical formulation according to claim 4 , wherein the antibody is at a concentration of at least 100 mg/ml.

6. The pharmaceutical formulation according to claim 4 , wherein the antibody is at a concentration of at least 200 mg/ml.

7. The pharmaceutical formulation according to claim 4 , wherein the antibody is at a concentration of at least 300 mg/ml.

8. The pharmaceutical formulation according to claim 4 , wherein the antibody is at a concentration of at least 500 mg/ml.

9. A kit comprising an anti-Factor D antibody of any one of claim 1 , 2 and 3 .

Assignees

• Genentech Inc

Inventors

• Kelley Robert F
• Van Lookeren Campagne Menno
• Scheer Justin M
• Hass Philip E
• Tesar Devin

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/14

  Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title

• A61P27/14

  Decongestants or antiallergics · CPC title

• A61P27/10

  for accommodation disorders, e.g. myopia · CPC title

• A61P27/02

  Ophthalmic agents · CPC title